Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Jaihwan Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0693-1415; OpenAlex author ID A5076089607, A5112566654, A5136262169. Sources: ClinicalTrials.gov.

Their work

Papers
47 (first author 2, last author 8)
Trials
1
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2013: 1 paper · 2014: 1 trial · 2015: 4 papers · 2016: 1 paper · 2017: 5 papers · 2018: 3 papers · 2019: 2 papers · 2020: 10 papers · 2021: 3 papers · 2022: 7 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 47

  1. Mass Spectrometry-Driven Proteomic Biomarkers for Serum-Based Detection of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm-Associa… Co-author DOI 10.1002/cam4.71941↗
  2. Comprehensive clinico-genomic analysis of pancreatic ductal adenocarcinoma: Overcoming biases and limitations. Co-author DOI 10.1016/j.canlet.2025.218176↗
  3. Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer. Co-author DOI 10.1186/s12885-025-14124-w↗
  4. Spatial transcriptomics reveal high T cell and monocyte status as predictive and prognostic markers in pancreatic cancer. Last author DOI 10.1186/s12967-025-06599-9↗
  5. Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. Co-author DOI 10.3389/fmicb.2025.1555479↗
  6. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. First author DOI 10.4251/wjgo.v17.i2.100167↗
  7. Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. Co-author DOI 10.5009/gnl240458↗
  8. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. Co-author DOI 10.1177/17588359241290482↗
  9. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. Last author DOI 10.5009/gnl230303↗
  10. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Co-author DOI 10.1177/17588359231175441↗
  11. Novel mRNA-based Immunological Biomarker for Early Detection of Resectable Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-2658368/v1↗
  12. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. Co-author DOI 10.1007/s00330-021-08494-5↗
  13. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. Last author DOI 10.1038/s41598-022-24732-2↗
  14. Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. Last author DOI 10.21037/jgo-22-218↗
  15. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. Co-author DOI 10.3233/cbm-210490↗
  16. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1050070↗
  17. Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14102476↗
  18. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic C… Co-author DOI 10.5009/gnl20312↗
  19. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A bi… Co-author DOI 10.1016/j.pan.2021.02.022↗
  20. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1038/s41598-021-99647-5↗
  21. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. Co-author DOI 10.1186/s13104-021-05681-x↗
  22. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 tria… Co-author DOI 10.1016/j.gie.2020.02.012↗
  23. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.06.010↗
  24. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. Co-author DOI 10.1038/s41598-020-73474-6↗
  25. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. Co-author DOI 10.1097/coc.0000000000000730↗
  26. Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer. Co-author DOI 10.1371/journal.pone.0238649↗
  27. The American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma: is it better than the 7th edition? First author DOI 10.21037/hbsn.2019.08.06↗
  28. Sex Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX Last author DOI 10.21203/rs.3.rs-33720/v1↗
  29. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. Co-author DOI 10.3390/cancers12113137↗
  30. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Co-author DOI 10.5009/gnl19180↗
  31. Involvement of the NF-κB signaling pathway in proliferation and invasion inhibited by Zwint-1 deficiency in Pancreatic Cancer Cells. Co-author DOI 10.7150/jca.46173↗
  32. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2019.06.002↗
  33. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and m… Co-author DOI 10.1038/s41598-019-52167-9↗
  34. It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. Last author DOI 10.1016/j.hbpd.2018.08.002↗
  35. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. Co-author DOI 10.1097/md.0000000000013592↗
  36. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. Co-author DOI 10.1136/bmjopen-2017-017249↗
  37. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Co-author DOI 10.1016/j.ejca.2017.02.010↗
  38. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.12.038↗
  39. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Co-author DOI 10.1097/md.0000000000005926↗
  40. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1010428317718403↗
  41. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0173960↗
  42. Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol. Co-author DOI 10.1136/bmjopen-2015-010491↗
  43. Postoperative early thromboembolism as a prognostic indicator in patients with curatively resected pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2014.12.051↗
  44. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/md.0000000000001012↗
  45. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. Co-author DOI 10.1111/cas.12744↗
  46. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma. Co-author DOI 10.3346/jkms.2015.30.3.259↗
  47. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 p… Co-author DOI 10.1371/journal.pone.0078977↗

Trials 1

  1. Comparison Between Base and Cover Slide From Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer Study chair NCT02190071↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 43 shared papers, 2015–2026 · strength 6.10
  2. Jong-Chan Lee · 31 shared papers, 2015–2026 · strength 4.83
  3. Kwangrok Jung · 13 shared papers, 2020–2026 · strength 2.69
  4. Yuna Youn · 7 shared papers, 2020–2026 · strength 1.30
  5. Jinwoo Ahn · 6 shared papers, 2022–2025 · strength 1.27
  6. Dong Woo Shin · 8 shared papers, 2019–2022 · strength 1.19
  7. Yoo‐Seok Yoon · 10 shared papers, 2015–2025 · strength 1.13
  8. Ho‐Seong Han · 10 shared papers, 2015–2025 · strength 1.13
  9. Jae Hyeong Kim · 5 shared papers, 2020–2026 · strength 0.90
  10. Jong-chan Lee · 7 shared papers, 2016–2022 · strength 0.82
  11. Jin Won Kim · 6 shared papers, 2017–2024 · strength 0.75
  12. Bo‐Mi Kim · 3 shared papers, 2023–2025 · strength 0.68
  13. Jae Hyup Jung · 4 shared papers, 2020–2024 · strength 0.68
  14. Young Hoon Kim · 5 shared papers, 2017–2022 · strength 0.65
  15. Haeryoung Kim · 6 shared papers, 2015–2022 · strength 0.64
  16. Hyoung Woo Kim · 6 shared papers, 2017–2020 · strength 0.58
  17. Yoon Suk Lee · 6 shared papers, 2015–2021 · strength 0.51
  18. Soomin Ahn · 3 shared papers, 2020–2025 · strength 0.51
  19. Min‐Jung Kang · 1 shared paper, 2026 · strength 0.43
  20. HyunGyo Jung · 1 shared paper, 2026 · strength 0.43
  21. Kyoung Un Park · 1 shared paper, 2025 · strength 0.23
  22. In Kuk Cho · 2 shared papers, 2018–2020 · strength 0.22
  23. Yeon Bi Han · 1 shared paper, 2025 · strength 0.22
  24. Ji Kon Ryu · 2 shared papers, 2013–2022 · strength 0.22
  25. Jinkook Kim · 2 shared papers, 2020 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.